Related Experiment Video
Updated: Jun 13, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis
1Wayne State University, Department of Neurology, 4201 St Antoine Street, Detroit, MI 48201, USA. atselis@med.wayne.edu
Abstract:
Laquinimod, a second-generation quinoline-3-carboxamide, is being developed by Active Biotech AB and Teva Pharmaceutical Industries Ltd for the treatment for relapsing-remitting multiple sclerosis (RRMS). Laquinimod has demonstrated significant activity in suppressing experimental autoimmune encephalomyelitis, an animal model of RRMS. In phase I and II clinical trials, the drug was well tolerated, with some hints of efficacy in small numbers of patients with RRMS. While the mechanism of action of the drug is unknown, it likely involves Th1 to Th2/Th3 immune deviation, promotion of the synthesis and release of neurotrophic factors, and other possible neuroprotective effects. Two phase III clinical trials are ongoing and, if successful, will lead to the approval of the first oral immunomodulatory drug for suppressing multiple sclerosis disease activity.
Related Concept Videos
Multiple Sclerosis l: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
